Prominent USC scientist goes on leave amid research misconduct allegations

Date:

Share post:


A prominent neuroscientist at USC is on leave nearly a year after allegations of research misconduct cast doubt on his published work and derailed trials for an experimental stroke treatment.

USC Keck School of Medicine Dean Carolyn Meltzer sent an email to faculty in the department of physiology and neuroscience on Oct. 22, disclosing that professor Berislav V. Zlokovic was on leave “for an indefinite period.”

In the email, Meltzer said that professor Steve Kay would serve as acting director of both the Zilkha Neurogenetic Institute and the department of physiology and neuroscience, positions that Zlokovic formerly held.

A spokesperson confirmed Zlokovic’s leave and Kay’s acting appointments on Monday but declined to provide further details, citing confidentiality surrounding personnel matters. Zlokovic didn’t immediately respond to requests for comment Monday.

Late last year, a group of whistleblowers submitted a report to the National Institutes of Health questioning the integrity of Zlokovic’s research and the safety of an experimental stroke treatment developed by ZZ Biotech, the company he co-founded.

The report identified allegedly doctored images and data in 35 research papers in which Zlokovic was the sole common author. It also questioned findings in the Phase II clinical trials of 3K3A-APC, a drug intended to reduce post-stroke brain bleeds.

The whistleblowers’ findings and news of Zlokovic’s leave were first reported in the journal Science.

On Sept. 26, Houston-based ZZ Biotech officially canceled 3K3A-APC’s clinical trial, according to a notice of withdrawal filed on the government’s database of clinical research studies.

“Any decisions on the future development pathway of 3K3A-APC in stroke will need to wait until the investigations of Dr. Zlokovic are complete,” ZZ Biotech Chief Executive Kent Pryor said Monday. Zlokovic no longer has any managerial or scientific affiliation with the company but remains a minority equity holder as co-founder, Pryor said.

NIH paused the trial in November 2023. It also launched an investigation into Zlokovic and instructed USC to return $1.9 million in funding already supplied for the study, Science reported.

A spokesperson for USC didn’t immediately respond to questions about the university’s obligations to return any federal money related to the study.

Zlokovic is a leading researcher on the blood-brain barrier, with particular interest in its role in stroke and dementia. After joining the USC faculty in 1989, he left and spent 11 years at the University of Rochester before returning to USC in 2011. He was appointed director of USC’s Zilkha Neurogenetic Institute the following year.

He retained his department chair and institute director titles as USC launched an investigation after the whistleblower report.

Since the allegations became public, three of Zlokovic’s hundreds of published research papers have been retracted. Eight more have been issued corrections or expressions of concern, a note journals append to articles when they believe there may be a problem with a paper but have not proved so.

Dr. Matthew Schrag, an assistant professor of neurology at Vanderbilt who co-authored the whistleblower report independently of his work at the university, previously told The Times that he and his colleagues did not find evidence of manipulated data in the drug trial. But given the degree of concern surrounding Zlokovic’s earlier work, he said, a clinical trial relying on his research to treat patients in life-threatening situations deserved further scrutiny.

“When you’re seeing a red flag or a trend in the clinical trial, I would tend to give that more weight in the setting of serious ethical concerns around the pre-clinical data,” Schrag said earlier this year. Schrag didn’t immediately respond to requests for comment Monday.



Source link

Lisa Holden
Lisa Holden
Lisa Holden is a news writer for LinkDaddy News. She writes health, sport, tech, and more. Some of her favorite topics include the latest trends in fitness and wellness, the best ways to use technology to improve your life, and the latest developments in medical research.

Recent posts

Related articles

Canadian teenager infected with H5N1 bird flu in critical condition

Canadian health officials announced Tuesday that a teenager infected with H5N1 bird flu from an unknown...

Surfboard lights might deter shark attacks — but don't bet your life on it

Australian researchers, who spent years towing seal-shaped decoys through waters infested with great white sharks, have...

JPL to lay off roughly 5% of its workforce

NASA’s Jet Propulsion Laboratory is preparing to lay off hundreds of employees this week, director Laurie...

Is this "slow" strength training method the fountain of youth? L.A.'s 90-year-olds say yes

DeLoyce Alcorn is 92 years old — and pressing nearly four times that in weight at...

Opinion: Too many older Americans are getting tested for Alzheimer's

An 80-something patient came in for an annual visit recently and was worried that recent memory...

Gas prices could rise after vote by California regulators

California air quality regulators late Friday approved tougher rules to encourage use of lower-carbon fuels, overriding...

Food, fluoride and funding: How a new Trump term might affect health in California

Donald Trump’s return to the White House stands to significantly shape the health of Californians —...

Are famous people more likely to die at 27, or does dying at 27 make them more famous?

Their deaths have fueled the notion that 27 is a lethal age for musicians and other...